<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079702</url>
  </required_header>
  <id_info>
    <org_study_id>AMCmedonc08/010</org_study_id>
    <nct_id>NCT01079702</nct_id>
  </id_info>
  <brief_title>Everolimus and Capecitabine in Patients With Advanced Malignancy</brief_title>
  <acronym>m-TOR</acronym>
  <official_title>A Phase I/II, Non-randomized, Multi-center, Dose-escalating, Two-stage Efficacy and Feasibility Study of the Combination of Everolimus and Capecitabine in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the investigators study the investigators combine everolimus, administrated twice daily at&#xD;
      a fixed total dose of 10 mg continuously with capecitabine administered bid for 14 days&#xD;
      followed by 7 days rest. In this study, capecitabine will be dose escalated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results form preclinical studies suggest that mTOR inhibitors are promising drugs for the&#xD;
      treatment of various types of cancer. Everolimus seems the most attractive mTOR inhibitor&#xD;
      because of the favourable pharmacokinetic profile and possibility of oral administration.&#xD;
      Based on preclinical findings, mTOR inhibitors may be more efficacious when used in a&#xD;
      rational combination with other cancer regiments like cytostatic drugs. Indeed, several&#xD;
      multiagent combinations are being investigated in clinical trials at the moment, and the&#xD;
      results are promising.&#xD;
&#xD;
      In our study we combine everolimus, administrated twice daily at a fixed total dose of 10 mg&#xD;
      continuously with capecitabine administered bid for 14 days followed by 7 days rest. In this&#xD;
      study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2&#xD;
      twice daily. Three patients will be enrolled per dose level, starting at dose level 1. If one&#xD;
      of the 3 patients develops dose-limiting toxicity at any dose level, 3 other patients will&#xD;
      start at the same dose level. If 2 or more out of these 6 patients develop DLT, no further&#xD;
      dose escalations will be performed. The MTD will be considered to be the dose given at the&#xD;
      previous lower level. No intrapatient dose escalation will be applied.&#xD;
&#xD;
      Once the MTD of capecitabine is established, the phase II part of the study will start in&#xD;
      which 25 patients with various malignancies will be enrolled to evaluate the efficacy and&#xD;
      feasibility of the combination of everolimus and capecitabine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I part: Assessment of dose limiting toxicity and maximum tolerated dose. II part: efficacy and feasibility. Primary endpoint of the study will be response rate.</measure>
    <time_frame>During treatment: assessments on day 1 every cycle (3 weeks). After treatment: every 3 months during the first 2 years, and every 6 months thereafter</time_frame>
    <description>Three patients will be enrolled per dose level, starting at dose level 1. If one of the 3 patients develops dose-limiting toxicity at any dose level, 3 other patients will start at the same dose level. If 2 or more out of these 6 patients develop DLT, no further dose escalations will be performed. The MTD will be considered to be the dose given at the previous lower level. No intrapatient dose escalation will be applied.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Every 3 months during the first 2 years, and every 6 months thereafter.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile.</measure>
    <time_frame>During treatment: assessments on day 1 every cycle (3 weeks). After treatment: every 3 months during the first 2 years, and every 6 months thereafter.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Advanced Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.</description>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.</description>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histological or cytological confirmed malignancies&#xD;
&#xD;
          -  Measurable lesion according to RECIST criteria (only for the phase II part of the&#xD;
             study)&#xD;
&#xD;
          -  ECOG / WHO performance status of 0-2&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Minimal acceptable safety laboratory values defined as:&#xD;
&#xD;
          -  WBC ≥ 3.0 x 109 /L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 109 /L&#xD;
&#xD;
          -  Hepatic function as defined by serum bilirubin ≤ 1.5 x ULN, ALT or AST ≤ 2.5 x ULN, in&#xD;
             case of liver metastases ≤ 5 x ULN&#xD;
&#xD;
          -  Renal function as defined by creatinine &lt; 150μmol/L&#xD;
&#xD;
          -  Able and willing to give written informed consent&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  Able and willing to undergo blood sampling for pharmacokinetic and pharmacogenetic&#xD;
             analysis&#xD;
&#xD;
          -  Mentally, physically and geographically able to undergo treatment and follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known alcoholism, drug addiction and/or psychotic disorders in the&#xD;
             history that are not suitable for adequate follow up&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Women of childbearing potential who refuse to use a reliable contraceptive method&#xD;
             throughout the study&#xD;
&#xD;
          -  Serious concomitant systemic disorder that would compromise the safety of the patient,&#xD;
             at the discretion of the investigator&#xD;
&#xD;
          -  Any other medical condition that would interfere with study procedures and/or decrease&#xD;
             safety of the protocol treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanneke Wilmink, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanneke Wilmink, MD, PhD</last_name>
    <phone>+31 205665955</phone>
    <email>j.w.wilmink@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dick Richel, MD, PhD</last_name>
    <phone>+31 205665955</phone>
    <email>d.j.richel@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanneke Wilmink, MD PhD</last_name>
      <phone>+31-20-5665955</phone>
      <phone_ext>58919</phone_ext>
      <email>j.w.wilmink@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lyda ter Hofstede</last_name>
      <phone>+31-20-5668229</phone>
      <email>trialmedonc@amc.uva.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanneke Wilmink, MD, PhD</last_name>
      <phone>+31 205665955</phone>
      <email>j.w.wilmink@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lyda ter Hofstede</last_name>
      <phone>+31 205668229</phone>
      <email>trialmedonc@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Hanneke Wilmink, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>March 2, 2010</last_update_submitted>
  <last_update_submitted_qc>March 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>J.W.Wilmink, MD PhD</name_title>
    <organization>Academisch Medisch Centrum-Universiteit Amsterdam (AMC-UvA)</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 26, 2014</submitted>
    <returned>September 4, 2014</returned>
    <submitted>January 7, 2020</submitted>
    <returned>January 21, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

